Evidence map›Paper›PMID 29774201›Full record

ArticleFrontiers in oncology2018

Investigation of Experimental Factors That Underlie

Vanessa L Lattimore, John F Pearson, Margaret J Currie, Amanda B Spurdle, kConFab Investigators, Bridget A Robinson, Logan C Walker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. QuantifyingInternational journal of molecular sciences · 2019
    Article
  3. Comprehensive Assessment ofFrontiers in genetics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Vanessa L LattimoreMackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
John F PearsonBiostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand.
Margaret J CurrieMackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Amanda B SpurdleGenetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
kConFab Investigators
Bridget A RobinsonMackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
Logan C WalkerMackenzie Cancer Research Group, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
University of Otago · NZChristchurch Hospital · NZQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PCR-based RNA splicing assays are commonly used in diagnostic and research settings to assess the potential effects of variants of uncertain clinical significance in

Indexed as

BRCA1BRCA2mRNAmRNA isoformsnext-generation sequencingquantitativesplicingtargeted next-generation sequencing

Identifiers

PMID29774201
PMCPMC5943536
OpenAlexW2800521124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.